E.S. van der Zaag
Gelre Hospitals
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by E.S. van der Zaag.
British Journal of Surgery | 2014
M. W. van den Berg; D. A. M. Sloothaak; Marcel G. W. Dijkgraaf; E.S. van der Zaag; W. A. Bemelman; P. J. Tanis; Robbert J. I. Bosker; P. Fockens; F. ter Borg; J. E. van Hooft
Endoscopic self‐expanding metal stent (SEMS) placement as a bridge to surgery is an option for acute malignant colonic obstruction. There is ongoing debate regarding the superiority and oncological safety of SEMS placement compared with emergency surgery. This retrospective study aimed to compare outcomes of these treatment approaches.
Ejso | 2009
E.S. van der Zaag; C. J. Buskens; N. Kooij; H. Akol; H. M. Peters; W. H. Bouma; W. A. Bemelman
AIMnTo compare the predictive value of sentinel lymph node (SN) mapping between patients with colon and rectal cancer.nnnPATIENTS AND METHODSnAn ex vivo SN procedure was performed in 100 patients with colon and 32 patients with rectal cancer. If the sentinel node was negative, immunohistochemical analyses using two different antibodies against cytokeratins (Cam5.2 and CK 20) and one antibody against BerEp-4 were performed to detect occult tumour cells. Isolated tumour cells (<0.2mm) were discriminated from micrometastases (0.2-2mm).nnnRESULTSnAn SN was identified in 117 patients (89%), and accurately predicted nodal status in 106 patients (accuracy 91%). Both sensitivity and negative predictive value were higher in colon carcinomas than in rectal carcinomas (83% versus 57%, p=0.06 and 93% versus 65%, p=0.002 respectively). In patients with extensive lymph node metastases the SN procedures were less successful. Eleven of the 13 unsuccessful SN procedures were performed in patients with rectal cancer who had pre-operative radiotherapy. After immunohistochemical analysis 21 of the 73 N0 patients had occult tumour cells in their SN; eight patients had micrometastases and 13 patients had isolated tumour cells.nnnCONCLUSIONnSN mapping accurately predicts nodal status in patients with colonic cancer. Immunohistochemical analysis demonstrates micrometastatic disease in eight out of 73 N0 patients, with a true upstaging rate of 11%. SN mapping is less reliable in patients with rectal cancer after pre-operative radiotherapy.
Ejso | 2014
D. A. M. Sloothaak; Saloomeh Sahami; H.J. van der Zaag-Loonen; E.S. van der Zaag; P. J. Tanis; W. A. Bemelman; C. J. Buskens
INTRODUCTIONnDetection of occult tumour cells in lymph nodes of patients with stage I/II colorectal cancer is associated with decreased survival. However, according to recent guidelines, occult tumour cells should be categorised in micrometastases (MMs) and isolated tumour cells (ITCs). This meta-analysis evaluates the prognostic value of MMs and of ITCs, separately.nnnMETHODSnPubMed, Embase, Biosis and the World Health Organization International Trials Registry Platform were searched for papers published until April 2013. Studies on the prognostic value of MMs and ITCs in lymph nodes of stage I/II colorectal cancer patients were included. Odds ratios (ORs) for the development of disease recurrence were calculated to analyse the predictive value of MMs and ITCs.nnnRESULTSnFrom five papers, ORs for disease recurrence could be calculated for MMs and ITCs separately. In patients with colorectal cancer, disease recurrence was significantly increased in the presence of MMs in comparison with absent occult tumour cells (OR 5.63; 95%CI 2.4-13.13). This was even more pronounced in patients with colon cancer (OR 7.25 95% CI 1.82-28.97). In contrast, disease recurrence was not increased in the presence of ITCs (OR 1.00 95% CI 0.53-1.88).nnnCONCLUSIONnPatients with stage I/II colorectal cancer and MMs have a worse prognosis than patients without occult tumour cells. However, ITCs do not have a predictive value. The distinction between ITCs and MMs should be made if the detection of occult tumour cells is incorporated in the clinical decision for adjuvant treatment.
Colorectal Disease | 2016
E.R.J. Bruns; B. van den Heuvel; C. J. Buskens; P. van Duijvendijk; Sebastiaan Festen; E. Wassenaar; E.S. van der Zaag; W. A. Bemelman; B. C. van Munster
Prehabilitation, defined as enhancement of the preoperative condition of a patient, is a possible strategy for improving postoperative outcome. Lack of muscle strength and poor physical condition, increasingly prevalent in older patients, are risk factors for postoperative complications. Eighty‐five per cent of patients with colorectal cancer are aged over 60 years. Since surgery is the cornerstone of their treatment, this review systemically examined the literature on the effect of physical prehabilitation in older patients undergoing colorectal surgery.
Ejso | 2015
Charlotte J. Verberne; Zhuozhao Zhan; E.R. van den Heuvel; I. Grossmann; P. M. Doornbos; Klaas Havenga; E. Manusama; Joost M. Klaase; H.C.J. Van Der Mijle; B. Lamme; K. Bosscha; Peter C. Baas; B. Van Ooijen; G.A.P. Nieuwenhuijzen; A. Marinelli; E.S. van der Zaag; D. Wasowicz; G. H. de Bock; T. Wiggers
AIMnThe value of frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging for detecting recurrent disease in colorectal cancer (CRC) patients was investigated in search for an evidence-based follow-up protocol.nnnMETHODSnThis is a randomized-controlled multicenter prospective study using a stepped-wedge cluster design. From October 2010 to October 2012, surgically treated non-metastasized CRC patients in follow-up were followed in eleven hospitals. Clusters of hospitals sequentially changed their usual follow-up care into an intensified follow-up schedule consisting of CEA measurements every two months, with imaging in case of two CEA rises. The primary outcome measures were the proportion of recurrences that could be treated with curative intent, recurrences with definitive curative treatment outcome, and the time to detection of recurrent disease.nnnRESULTSn3223 patients were included; 243 recurrences were detected (7.5%). A higher proportion of recurrences was detected in the intervention protocol compared to the control protocol (OR = 1.80; 95%-CI: 1.33-2.50; p = 0.0004). The proportion of recurrences that could be treated with curative intent was higher in the intervention protocol (OR = 2.84; 95%-CI: 1.38-5.86; p = 0.0048) and the proportion of recurrences with definitive curative treatment outcome was also higher (OR = 3.12, 95%-CI: 1.25-6.02, p-value: 0.0145). The time to detection of recurrent disease was significantly shorter in the intensified follow-up protocol (HR = 1.45; 95%-CI: 1.08-1.95; p = 0.013).nnnCONCLUSIONnThe CEAwatch protocol detects recurrent disease after colorectal cancer earlier, in a phase that a significantly higher proportion of recurrences can be treated with curative intent.
Ejso | 2010
E.S. van der Zaag; N. Kooij; M.J. van de Vijver; W. A. Bemelman; H. M. Peters; C. J. Buskens
PURPOSEnMost studies on the sentinel node (SN) procedure in patients with colorectal cancer include immunohistochemical analysis of the SN only. To evaluate the real diagnostic accuracy of the SN procedure with immunohistochemical analysis, the presence of occult tumour cells in all histologically negative lymph nodes was compared to the presence of these cells in SNs. Also the reproducibility of diagnosing occult tumour cells (OTC) and the sensitivity of three different antibodies was assessed.nnnMETHODSnBetween November 2006 en July 2007, an ex vivo SN procedure was performed in 58 histologically N0 patients with colorectal cancer. All lymph nodes (n = 908, mean 15.7) were step-sectioned and immunohistochemistry was performed using two antibodies against cytokeratins (Cam5.2, and CK 20) and one antibody against BerEp-4.nnnRESULTSnOTC were identified in 19 of 58 patients, with micrometastases (0.2-2 mm) in 7 and isolated tumour cells (ITC)(<0.2 mm) in 12 patients. The overall agreement in diagnosing OTC between two independent pathologists was 86%. An SN was identified in 53 of 58 patients. All micrometastases were found in SNs. In two patients with negative SNs, ITCs were demonstrated in non-SNs (sensitivity 88%, and overall accuracy 96%).nnnCONCLUSIONnAdditional immunohistochemical analysis of histologically negative lymph nodes demonstrates occult tumour cells in 33% of the patients resulting in an upstaging rate of 12%. Occult tumour cells are predominantly found in the SN, therefore SN mapping has the potential to refine the staging system for patients with colorectal cancer.
British Journal of Surgery | 2014
D. A. M. Sloothaak; S. Grewal; H. Doornewaard; P. van Duijvendijk; P. J. Tanis; W. A. Bemelman; E.S. van der Zaag; C. J. Buskens
In colonic cancer, the number of harvested lymph nodes is associated with prognosis. The aim of this study was to determine the contribution of small lymph nodes to pathological staging, and to analyse the hypothesis that node size is a confounder in the relationship between prognosis and nodal harvest.
Ejso | 2015
Johannes A. Govaert; Marta Fiocco; W.A. van Dijk; A.C. Scheffer; E. J. R. de Graaf; R.A.E.M. Tollenaar; Michel W.J.M. Wouters; B. Lamme; D.A. Hess; H.J. Belgers; O.R. Guicherit; Camiel Rosman; H.J.T. Rutten; F.N.L. Versluijs-Ossewaarde; E.S. van der Zaag; Larissa N. L. Tseng; W.J. Vles; E.G.J.M. Pierik; Hubert A. Prins; P.H.M. Reemst; E. C. J. Consten; S.A. Koopal; Peter A. Neijenhuis; Guido Mannaerts; Anke B. Smits; D.H.C. Burger; M.G.A. van Ijken; P. Poortman; Marc J.P.M. Govaert; W.A. Bleeker
BACKGROUNDnHealthcare providers worldwide are struggling with rising costs while hospitals budgets are under stress. Colorectal cancer surgery is commonly performed, however it is associated with a disproportionate share of adverse events in general surgery. Since adverse events are associated with extra hospital costs it seems important to explicitly discuss the costs of complications and the risk factors for high-costs after colorectal surgery.nnnMETHODSnRetrospective analysis of clinical and financial outcomes after colorectal cancer surgery in 29 Dutch hospitals (6768 patients). Detailed clinical data was derived from the 2011-2012 population-based Dutch Surgical Colorectal Audit database. Costs were measured uniform in all participating hospitals and based on Time-Driven Activity-Based Costing.nnnFINDINGSnOf total hospital costs in this study, 31% was spent on complications and the top 5% most expensive patients were accountable for 23% of hospitals budgets. Minor and severe complications were respectively associated with a 26% and 196% increase in costs as compared to patients without complications. Independent from other risk factors, ASA IV, double tumor, ASA III, short course preoperative radiotherapy and TNM-4 stadium disease were the top-5 attributors to high costs.nnnCONCLUSIONSnThis article shows that complications after colorectal cancer surgery are associated with a substantial increase in costs. Although not all surgical complications can be prevented, reducing complications will result in considerable cost savings. By providing a business case we show that investments made to develop targeted quality improvement programs will pay off eventually. Results based on this study should encourage healthcare providers to endorse quality improvement efforts.
Ejso | 2016
C.C. Margadant; E.R.J. Bruns; D.A.M. Sloothaak; P. van Duijvendijk; A.F. van Raamt; H.J. van der Zaag; C. J. Buskens; B.C. van Munster; E.S. van der Zaag
BACKGROUNDnReduced muscle density is associated with an increased risk of postoperative complications. We examined the prognostic value of muscle density as a predictor of postoperative complications in elderly patients undergoing surgery for colorectal cancer.nnnMETHODSnPatients (≥70 years) who underwent surgery for colorectal cancer between 2006 and 2013 were selected from a prospective single centre database. The Hounsfield Unit Average (HUA or HU/mm2) of the psoas muscles at the level of the third lumbar vertebra was calculated on the scan. High and low muscle density groups were identified based on the lowest gender specific HUAC quartile. Major postoperative complications (Clavien-Dindo (CD) ≥3) within 30 days after surgery were retrospectively documented. Logistic regression analysis was used to identify risk factors for postoperative complications.nnnRESULTSnA total of 373 patients (median agexa0=xa078 years) were included in this study. The mean muscle density score was 24.5xa0±xa04.3xa0HU/mm2 for males and 26.3xa0±xa05.0xa0HU/mm2 for females. The cut-off point for the lowest gender specific quartile wasxa0≤22.0xa0HU/mm2 for males and ≤23.5xa0HU/mm2 for females. After multivariable regression, there was a statistically significant association between muscle density and CDxa0≥xa03 (ORxa0=xa01.84 (95% CI 1.11-3.06), pxa0=xa00.019). Anastomotic leakage in patients with a primary anastomosis (nxa0=xa0287) occurred more often in patients with low muscle density (11.7% vs 23.3%, pxa0=xa00.016). The associations remained significant after correction for confounders.nnnCONCLUSIONnLow muscle density is associated with major postoperative complications in older patients who undergo surgery for colorectal cancer.
Ejso | 2017
D. A. M. Sloothaak; R.L.A. van der Linden; C.J.H. van de Velde; W. A. Bemelman; D.J. Lips; J.C. van der Linden; H. Doornewaard; P. J. Tanis; K. Bosscha; E.S. van der Zaag; C. J. Buskens
INTRODUCTIONnOccult nodal tumour cells should be categorised as micrometastasis (MMs) and isolated tumour cells (ITCs). A recent meta-analysis demonstrated that MMs, but not ITCs, are prognostic for disease recurrence in patients with stage I/II colon cancer.nnnAIMS & METHODSnThe objective of this retrospective multicenter study was to correlate MMs and ITCs to characteristics of the primary tumour, and to determine their prognostic value in patients with stage I/II colon cancer.nnnRESULTSnOne hundred ninety two patients were included in the study with a median follow up of 46 month (IQR 33-81 months). MMs were found in eight patients (4.2%), ITCs in 37 (19.3%) and occult tumour cells were absent in 147 patients (76.6%). Between these groups, tumour differentiation and venous or lymphatic invasion was equally distributed. Advanced stage (pT3/pT4) was found in 66.0% of patients without occult tumour cells (97/147), 72.9% of patients with ITCs (27/37), and 100% in patients with MMs (8/8), although this was a non-significant trend. Patients with MMs showed a significantly reduced 3 year-disease free survival compared to patients with ITCs or patients without occult tumour cells (75.0% versus 88.0% and 94.8%, respectively, pxa0=xa00.005). When adjusted for T-stage, MMs independently predicted recurrence of cancer (OR 7.6 95% CI 1.5-37.4, pxa0=xa00.012).nnnCONCLUSIONnIn this study, the incidence of MMs and ITCs in patients with stage I/II colon cancer was 4.2% and 19.3%, respectively. MMs were associated with an reduced 3 year disease free survival rate, but ITCs were not.